Finally, the remaining three top candidate methylation markers (DOCK2, FBXO30-cg23095612, and HAPLN3; Table S6) were selected for large-scale evaluation in the clinical cohort (n = 241), as they showed no false-positive signals and also had high sensitivity/specificity for PCa in the technical validation phase (Figure 1). This evidence concerns the gene DOCK2 and posterior cortical atrophy.